Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis.
about
Bacterial sexually transmitted infections: current management strategies.Concurrent gonococcal and chlamydial infection: how best to treat.Treatment of uncomplicated genital Chlamydia trachomatis infections in adults.Azithromycin for PID beats doxycycline on all counts.The efficacy of oral azithromycin in clearing ocular chlamydia: mathematical modeling from a community-randomized trachoma trial.Estimating the direct costs of pelvic inflammatory disease in adolescents: a within-system analysis.Cost effectiveness analysis of azithromycin and doxycycline for Chlamydia trachomatis infection in women: A Canadian perspective.Optimizing treatment of antimicrobial-resistant Neisseria gonorrhoeaeCost-effectiveness of universal screening for chlamydia and gonorrhea in US jailsScreening for Chlamydia trachomatis: a systematic review of the economic evaluations and modellingAzithromycin (zithromax).Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States.Chlamydiae as pathogens: new species and new issues.Need for screening for genital Chlamydia trachomatis infection in Australia.European guideline for the management of chlamydial infection.The 1998 CDC Sexually Transmitted Diseases Treatment Guidelines.Single dose oral azithromycin versus seven day doxycycline in the treatment of non-gonococcal mucopurulent endocervicitis.Cost-effectiveness of prophylactic dolasetron or droperidol vs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery.Controlling genital chlamydial infection.Cost-effectiveness analysis of abciximab: a Canadian hospital perspective.
P2860
Q33631003-2D476AD1-15B6-4528-BB7D-9C8763D2D201Q33914352-752F0F4F-21FB-4DDB-8C67-2296F42B98CAQ34918503-4207B25A-9392-402F-9670-67C3A01A0D15Q35246485-2954C284-7B7C-4336-87D7-FC7A74AA9335Q35571651-A63B0736-D93D-465C-8F64-F018BE6AAA77Q35612727-FD07D743-B067-442D-86B4-1AB0F760607AQ35650139-029D662B-4263-437C-9C92-0BF87C5FF49EQ35873375-52E86550-A4CE-42A3-B2B4-39A8F1282CAFQ36272418-A3E36E02-CA51-4BA8-A106-B5C54B318D25Q36491361-E3C1F1F0-3F31-4568-9F9F-29BE9E93C884Q36625096-316B33E3-24EA-4BAC-9DF2-7DD9476A36C5Q36717723-2BD3FC4F-8C06-4316-A972-BA78ACE543F3Q36838445-1870FFD2-B777-46B0-96DA-670AE6F3DE5CQ37867937-AA4EF021-1762-4DF2-8F67-75CB413E6CA8Q37873289-7E2BFC30-F061-488A-AE92-F88D36399D45Q37875254-7FB387B7-7DF5-4199-B43D-AC1AA02AFF53Q37876192-6F8B2B1C-98F0-4481-B6F0-B6383B9ACB2FQ40807325-EC764002-7759-4080-B774-41DA9365726DQ43190453-029E1211-C066-4076-99D9-14D72C845808Q48027994-E8742F75-262F-4576-A8B0-BFAAB58D8668
P2860
Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Doxycycline compared with azit ...... l cost-effectiveness analysis.
@en
Doxycycline compared with azit ...... l cost-effectiveness analysis.
@nl
type
label
Doxycycline compared with azit ...... l cost-effectiveness analysis.
@en
Doxycycline compared with azit ...... l cost-effectiveness analysis.
@nl
prefLabel
Doxycycline compared with azit ...... l cost-effectiveness analysis.
@en
Doxycycline compared with azit ...... l cost-effectiveness analysis.
@nl
P2093
P1476
Doxycycline compared with azit ...... l cost-effectiveness analysis.
@en
P2093
Douglas JM Jr
Schwartz JS
P304
P356
10.7326/0003-4819-124-4-199602150-00002
P407
P577
1996-02-01T00:00:00Z